Dr. David E. Cohn, Ohio State University Medical Center (VIDEO)

Ohio State University Wexner Medical Center

Caption

Dr. David E. Cohn discusses an analysis conducted by Ohio State University cancer researchers that found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective. The findings comparing the relative value of various clinical strategies will be published online March 7 in the Journal of Clinical Oncology.

Credit

Ohio State University Medical Center

Usage Restrictions

Embargoed until 4 p.m. EST March 7, 2011

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.